Autoimmune Disease Treatment Market Size, Share, Growth, Trends and Industry Analysis, By Type (Immunosuppressant’s, Anti-Inflammatory Drugs, Corticosteroids, Nonsteroidal Anti-inflammatory Drugs), By Application (Hospitals, Clinics, Drug Stores, Other), Regional Insights and Forecast From 2026 To 2035

• 

  Download Free Sample to learn more about this report

AUTOIMMUNE DISEASE TREATMENT MARKET OVERVIEW

The autoimmune disease treatment market globally is expected to be valued at USD 113.17 Billion in 2026. It is forecasted to increase to USD 144.29 Billion by 2035. This reflects a compound annual growth rate CAGR of 2.4% between 2026 to 2035.

The autoimmune disease treatment market focuses on therapies that calm abnormal immune responses in conditions such as rheumatoid arthritis, psoriasis, lupus, multiple sclerosis, Crohn's disease and type 1 diabetes. More than 80 autoimmune diseases are recognized, which creates demand for broad treatment options ranging from corticosteroids and immunosuppressants to targeted biologics and oral small molecules. Growing diagnosis rates, earlier specialist referral and long term disease management needs keep patients on therapy for years. Pharmaceutical companies are investing in precision immunology, cell therapies, bispecific antibodies and once-daily oral drugs to improve remission rates and reduce steroid exposure across the autoimmune disease treatment market.

The United States autoimmune disease treatment market benefits from advanced rheumatology, dermatology and gastroenterology care, strong insurance coverage and rapid adoption of novel therapies. The Food and Drug Administration plays a central role by granting breakthrough designations and approving new indications that expand treatment options for patients with limited choices. Specialty pharmacies, infusion centers and hospital systems coordinate complex biologic therapy, while patient advocacy groups raise awareness and support earlier diagnosis. American biotechnology companies lead clinical research in cell therapies, bispecific antibodies and oral targeted drugs. Payer scrutiny, biosimilar competition and prior authorization requirements shape prescribing, but demand remains strong because chronic autoimmune conditions require continuous disease management.

KEY FINDINGS

LATEST TRENDS

Oral targeted therapies are changing treatment expectations in the autoimmune disease treatment market. Johnson & Johnson's icotrokinra, approved for plaque psoriasis, was supported by a clinical program that enrolled approximately 2,500 patients, and 85% of patients with genital psoriasis achieved clear or almost clear skin at week 52. Results like these show that once-daily pills can approach the performance of injectable biologics. Cell therapy is another major trend. Developers are moving CAR T approaches from oncology into lupus, myasthenia gravis and other B-cell driven conditions, and in vivo programs aim to reprogram cells without complex manufacturing. Bispecific antibodies and T cell engagers are also advancing because they deplete pathogenic B cells more deeply than conventional treatments.

Precision immunology is gaining ground as companies segment patients by disease activity and biomarkers. Treatments that remove specific autoantibodies or restore immune tolerance aim to change disease course rather than only suppress symptoms. Subcutaneous autoinjectors and at-home administration are improving adherence, while digital monitoring supports earlier flare detection. Large pharmaceutical companies are also using acquisitions and licensing to expand immunology pipelines, and new indications such as Sjögren's disease, IgG4-related disease and dermatomyositis are receiving attention. Together, these trends are pushing the autoimmune disease treatment market toward more targeted, convenient and durable therapies.

•   
•   
  

  Download Free Sample to learn more about this report

    

AUTOIMMUNE DISEASE TREATMENT MARKET SEGMENTATION

By Type

Based on Type the global market can be categorized in to Immunosuppressants, Anti-Inflammatory Drugs, Corticosteroids, Nonsteroidal Anti-inflammatory Drugs and Biologics.

• Immunosuppressants: Immunosuppressants hold a 16% share of the autoimmune disease treatment market, supported by widespread use in rheumatoid arthritis, lupus, psoriasis, and inflammatory bowel disease management. Medications such as methotrexate, azathioprine, mycophenolate, and cyclosporine help control abnormal immune responses and reduce disease activity. Their established clinical effectiveness, affordability, and availability make them important treatment options across healthcare settings. However, infection risks, potential organ toxicity, and regular monitoring requirements influence prescribing decisions. Increasing adoption of targeted immunotherapies and precision medicine approaches is encouraging pharmaceutical manufacturers to develop treatments with improved safety profiles and more selective immune modulation.

• Anti-Inflammatory Drugs: Anti-Inflammatory Drugs account for an 11% share of the autoimmune disease treatment market, driven by demand for therapies that control inflammatory symptoms and support long-term disease management. These medications are used in dermatological, rheumatological, and gastrointestinal conditions to reduce inflammation and improve patient comfort. Growing availability of generic medicines, improved drug formulations, and convenient administration options supports treatment accessibility. Pharmaceutical companies are developing advanced anti-inflammatory therapies that target specific inflammatory pathways while reducing unwanted systemic effects. Increasing emphasis on personalized treatment plans and combination therapy approaches is strengthening the importance of these medications in autoimmune disease management.

• Corticosteroids: Corticosteroids represent an 18% share of the autoimmune disease treatment market, supported by their effectiveness in rapidly controlling inflammation and managing acute autoimmune disease flare-ups. Prednisone, methylprednisolone, dexamethasone, and topical corticosteroids are commonly prescribed for lupus, multiple sclerosis relapses, vasculitis, and inflammatory bowel disease. Their affordability, rapid therapeutic action, and broad availability make them essential medications in hospitals and outpatient healthcare settings. However, prolonged treatment can increase the risk of osteoporosis, metabolic complications, infections, and cardiovascular problems. Growing demand for steroid-sparing therapies is encouraging the development of targeted treatments that provide sustained disease control with fewer long-term adverse effects.

• Nonsteroidal Anti-inflammatory Drugs: Nonsteroidal Anti-inflammatory Drugs hold a 13% share of the autoimmune disease treatment market, supported by widespread use in managing pain, swelling, and joint stiffness associated with inflammatory autoimmune conditions. Medications such as ibuprofen, naproxen, diclofenac, and selective COX-2 inhibitors provide symptomatic relief for patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. Their accessibility through retail pharmacies and healthcare facilities supports continued demand. However, gastrointestinal complications, kidney-related risks, and cardiovascular safety concerns influence treatment duration and prescribing practices. Increasing emphasis on patient safety and combination treatment strategies continues to shape the role of these medications in supportive autoimmune disease care.

• Biologics: Biologics dominate the autoimmune disease treatment market with a 42% share, supported by increasing adoption of targeted immunotherapies for complex and chronic autoimmune disorders. These treatments include tumor necrosis factor inhibitors, interleukin inhibitors, B-cell-targeting therapies, and advanced monoclonal antibodies used in rheumatoid arthritis, psoriasis, lupus, and inflammatory bowel disease. Their ability to selectively target immune pathways supports improved disease control in appropriately selected patients. Pharmaceutical manufacturers are investing in next-generation antibodies, bispecific therapies, and innovative biologic delivery systems to improve treatment outcomes. Expanding biosimilar availability, growing specialist prescribing, and advancements in personalized medicine are strengthening competition and treatment accessibility.

By Application

Based on Application, the global autoimmune disease treatment market can be categorized into Hospitals, Clinics, Drug Stores, and Other.

• Hospitals: Hospitals dominate the autoimmune disease treatment market with a 49% share, supported by demand for specialized diagnosis, advanced therapeutic procedures, and multidisciplinary disease management. Hospital-based rheumatology, neurology, dermatology, and gastroenterology departments provide treatment for severe autoimmune disorders requiring close medical supervision. Advanced diagnostic laboratories, infusion facilities, and specialized pharmacy services support the administration of biologics, immunosuppressants, and complex therapeutic regimens. Academic hospitals also contribute to clinical research and the development of innovative autoimmune treatments. Increasing availability of targeted immunotherapies and advanced treatment infrastructure continues to strengthen the role of hospitals in managing complicated autoimmune conditions.

• Clinics: Clinics account for a 23% share of the autoimmune disease treatment market, driven by increasing demand for outpatient diagnosis, regular disease monitoring, and personalized treatment management. Specialized rheumatology, dermatology, gastroenterology, and endocrinology clinics provide ongoing care for patients requiring long-term autoimmune disease treatment. Growing adoption of oral targeted therapies, telemedicine consultations, and digital patient monitoring technologies is improving treatment accessibility. Clinics also coordinate laboratory testing, medication adjustments, and patient education to support adherence and disease control. Expanding specialist healthcare networks and increasing emphasis on preventive management are strengthening outpatient treatment services.

• Drug Stores: Drug Stores hold a 21% share of the autoimmune disease treatment market, supported by increasing demand for prescription medications, chronic disease maintenance therapies, and convenient pharmaceutical access. Retail and specialty pharmacies distribute corticosteroids, immunosuppressants, nonsteroidal anti-inflammatory drugs, and approved oral targeted therapies. Pharmacists provide medication counseling, treatment adherence support, and guidance regarding potential drug interactions and adverse effects. Growing adoption of online pharmacies, home delivery services, and digital prescription management is improving patient convenience. Expanding availability of generic medications and biosimilars through appropriate pharmacy channels is also supporting treatment affordability and accessibility.

• Other: Other applications represent a 7% share of the autoimmune disease treatment market, including home healthcare services, specialty infusion centers, telemedicine platforms, long-term care facilities, and clinical research institutions. Increasing adoption of self-administered biologics, home infusion services, and remote patient monitoring is supporting treatment outside traditional healthcare facilities. Digital healthcare technologies enable specialists to assess symptoms, review laboratory results, and adjust treatment plans without frequent hospital visits. Patient assistance programs and specialized nursing services are improving medication adherence and continuity of care. Growing emphasis on decentralized healthcare delivery and personalized disease management is creating additional opportunities across alternative treatment settings.

MARKET DYNAMICS

Driving Factor

Rising prevalence and earlier diagnosis of autoimmune diseases

Autoimmune conditions are chronic, and their prevalence is increasing as awareness, screening and specialist access improve. In the United States alone, up to 4 million people have Sjögren's disease, which shows how large patient pools can be even for less visible conditions. Earlier diagnosis keeps more patients in long term care, and complex diseases such as rheumatoid arthritis, lupus, psoriasis, inflammatory bowel disease and multiple sclerosis often require lifelong therapy. Aging populations, environmental triggers, genetic testing and better biomarkers further widen the treated population. Because patients typically cycle through several drug classes, demand expands for corticosteroids, immunosuppressants and advanced biologics, which supports sustained growth in the autoimmune disease treatment market.

Drivers Impact Analysis*

Restraining Factor

High cost of biologics and limited patient access

Biologics and other advanced therapies carry high prices, complex administration and strict payer rules, which can delay treatment. Prior authorization, step therapy and formulary limits require patients to try cheaper options before accessing targeted drugs, while out-of-pocket costs reduce adherence. Healthcare systems in emerging markets face budget limits, and infusion capacity can be a bottleneck in hospitals. Biosimilar competition also pressures prices for older biologics, which makes return on development more difficult for manufacturers. Side effects such as infection risk require monitoring and add care costs. These access barriers restrain broader adoption in the autoimmune disease treatment market, even where clinical benefits are well established.

Restraints Impact Analysis*

Expansion of oral targeted drugs, cell therapies and precision immunology

Opportunity

Oral targeted drugs offer convenient alternatives to injections and infusions, which can attract patients who prefer simple routines and expand use earlier in treatment. Cell therapies and bispecific antibodies create potential for deeper, longer lasting remission in lupus, myasthenia gravis and other severe conditions. Conditions with few or no approved therapies, such as Sjögren's disease, represent significant unmet need and strong first-mover potential. Biomarker-based patient selection can improve response rates and reduce trial failures. Collaborations with biotechnology firms also give large pharmaceutical companies access to early platforms and shorten development timelines.

Complex disease biology and clinical development risk

Challenge

Autoimmune diseases are heterogeneous, so patients with the same diagnosis can respond very differently to the same drug. This complexity makes trial design difficult, raises development costs and increases the chance of late-stage failure. Safety is another concern because suppressing immune pathways can raise infection and malignancy risk. Long term outcome data are needed to convince regulators, physicians and payers, particularly for novel cell therapies. Manufacturing complexity, cold chain logistics and specialized treatment centers add further hurdles.

•   
•   
  Download Free Sample to learn more about this report

    

AUTOIMMUNE DISEASE TREATMENT MARKET REGIONAL INSIGHTS

• North America

North America dominates the autoimmune disease treatment market with a 44% market share, supported by advanced healthcare infrastructure, strong insurance coverage, and increasing adoption of innovative immunotherapies. The United States leads regional demand through extensive clinical research activities, regulatory approvals, and established specialist treatment networks. Major pharmaceutical companies, including Eli Lilly, Amgen, Pfizer, Bristol Myers Squibb, and Johnson & Johnson, are investing in biologics, targeted therapies, and precision medicine technologies. Growing awareness of autoimmune disorders, early diagnosis, and expanding specialty pharmacy services are supporting treatment accessibility.

• Europe

Europe accounts for a 28% market share in the autoimmune disease treatment market, driven by established healthcare systems, strong pharmaceutical research capabilities, and widespread adoption of biosimilar therapies. Germany, France, the United Kingdom, Italy, and Spain remain important regional markets, supported by specialized rheumatology, dermatology, and neurology services. European Medicines Agency approvals and national reimbursement policies influence treatment accessibility and pharmaceutical innovation. Increasing investment in monoclonal antibodies, targeted immunotherapies, and advanced biologic development is strengthening regional competitiveness.

• Asia Pacific

Asia Pacific holds a 17% market share in the autoimmune disease treatment market, supported by improving healthcare infrastructure, increasing disease awareness, and expanding access to advanced therapeutic options. China, Japan, India, South Korea, and Australia represent important regional markets, driven by growing specialist healthcare services and pharmaceutical manufacturing capabilities. Increasing adoption of biologics, biosimilars, and targeted immunosuppressive therapies is strengthening treatment availability. Regional pharmaceutical companies are investing in biotechnology research, clinical development, and affordable generic medicines.

• Middle East & Africa

Middle East & Africa represents a 6% market share in the autoimmune disease treatment market, supported by increasing healthcare investment, expanding specialist treatment facilities, and improving awareness of chronic autoimmune disorders. Saudi Arabia, the United Arab Emirates, South Africa, and Egypt are important regional markets, driven by hospital infrastructure development and increasing availability of advanced pharmaceutical therapies. Government healthcare modernization programs and international pharmaceutical partnerships are improving access to biologics and immunosuppressive treatments. Growing investment in rheumatology, dermatology, and neurological care is strengthening regional treatment capabilities.

• Rest of the World

Rest of the World accounts for a 5% market share in the autoimmune disease treatment market, covering Latin America and other emerging markets outside the major regional classifications. Brazil, Argentina, Colombia, and other developing economies are experiencing increasing demand for autoimmune therapies through expanding healthcare services and improving disease awareness. Growing adoption of generic immunosuppressants, biosimilars, and targeted biologic treatments is supporting pharmaceutical accessibility. Government procurement programs, regional pharmaceutical partnerships, and healthcare infrastructure investments are creating opportunities for market expansion. However, medicine affordability, import dependence, and limited specialist availability remain important challenges.

KEY INDUSTRY PLAYERS

The autoimmune disease treatment market is led by global pharmaceutical and biotechnology companies with deep immunology pipelines, strong clinical development capabilities and broad commercial reach. Major vendors include Johnson & Johnson, Amgen, Pfizer, Bristol-Myers Squibb, Eli Lilly, F. Hoffmann-La Roche Ltd., GlaxoSmithKline and AstraZeneca plc. Emerging players such as Active Biotech and 4SC AG focus on specialized small molecules and niche indications. Competitive strategies include acquisitions, licensing agreements, label expansion, oral drug development and cell therapy collaboration. Partnerships with biotechnology firms give large companies access to novel platforms, while patient support programs and specialty distribution strengthen market positioning.

List of Top Autoimmune Disease Treatment Companies

• Abbott Laboratories
• Active Biotech
• Eli Lilly
• Bristol-Myers Squibb
• AstraZeneca plc
• Pfizer
• Biogen Idec
• Lupin Limited
• GlaxoSmithKline
• Amgen
• 4SC AG
• F. Hoffmann-La Roche Ltd.
• AutoImmune Inc
• Johnson & Johnson
• Bayer

LEADER INSIGHTS

• Johnson & Johnson: Joaquin Duato Chairman and Chief Executive Officer, emphasized that expanding adoption of targeted immunology treatments is strengthening opportunities across inflammatory bowel disease and psoriatic conditions. His outlook highlights sustained demand for differentiated biologics and continued investment in innovative therapies addressing unmet patient needs. (Published: October 13, 2026 | Source: https://www.jnj.com/)

• Amgen: Dr. Paul Burton Senior Vice President and Chief Medical Officer, highlighted the importance of advancing innovative treatments and expanding real-world clinical evidence for rare and serious autoimmune diseases. His comments reflect growing opportunities to address unmet medical needs through targeted immunotherapies, long-term treatment evidence, and broader understanding of complex immune-mediated conditions. (Published: October 27, 2026 | Source: https://investors.amgen.com/)

• Eli Lilly: Dr. Francisco Ramírez-Valle Senior Vice President, Immunology Research and Early Clinical Development, emphasized the potential of precision therapies that selectively eliminate disease-causing autoantibodies while preserving normal immune function. His comments highlight opportunities to expand this therapeutic approach across antibody-driven autoimmune diseases, supporting strategic investment in next-generation immunology treatments and disease-modifying innovation. (Published: August 31, 2026 | Source: https://investor.lilly.com/)

INVESTMENT ANALYSIS AND OPPORTUNITIES

Investment in the autoimmune disease treatment market is increasingly focused on advanced cell therapies, antibody engineering, precision immunology, and targeted treatment development. Bristol Myers Squibb agreed to acquire Orbital Therapeutics for USD 1.5 billion, strengthening its position in next-generation cell therapies for autoimmune disorders. Pharmaceutical companies and biotechnology developers are expanding investments in innovative immunomodulators, steroid-sparing treatments, oral targeted therapies, and personalized medicine platforms. Growing demand for effective treatments for chronic autoimmune conditions is creating opportunities for research collaborations, strategic acquisitions, and clinical development programs. Emerging healthcare markets also offer investment potential through specialty treatment centers, biosimilar manufacturing, digital healthcare platforms, and improved pharmaceutical distribution networks.

NEW PRODUCT DEVELOPMENT

New product development in the autoimmune disease treatment market emphasizes targeted immune modulation, convenient drug administration, improved treatment efficacy, and reduced long-term adverse effects. Johnson & Johnson advanced icotrokinra, an oral peptide therapy targeting the IL-23 receptor, with 72% of patients in a reported clinical assessment achieving clear or almost clear scalp psoriasis. Pharmaceutical manufacturers are developing advanced monoclonal antibodies, bispecific therapies, selective immune inhibitors, and innovative cell-based treatments to address complex autoimmune conditions. Increasing emphasis on oral formulations, self-administered injections, and precision medicine is improving treatment convenience and supporting patient adherence. Continued research into immune tolerance and disease-modifying mechanisms is creating opportunities for next-generation autoimmune therapies.

RECENT DEVELOPMENTS

• September 2026: Amgen reported positive pivotal clinical trial findings for dazodalibep, an investigational CD40L-targeting fusion protein developed for Sjögren's disease. The treatment demonstrated improvements in disease-related signs and symptoms, supporting continued regulatory development.

• August 2026: Eli Lilly announced an agreement to acquire Merida Biosciences, strengthening its autoimmune disease research portfolio through advanced antibody-engineering technologies. The acquisition focuses on therapeutic approaches designed to selectively eliminate pathogenic autoantibodies associated with autoimmune disorders.

• March 2026: Johnson received FDA approval for icotrokinra, an oral peptide therapy targeting the IL-23 receptor for plaque psoriasis. The treatment introduces an alternative to injectable biologic therapies for eligible patients.

• October 2025: Bristol Myers Squibb announced an agreement to acquire Orbital Therapeutics, strengthening its development pipeline in advanced autoimmune cell therapies. The transaction includes an investigational in vivo CAR T-cell program designed to modify immune cells directly within the patient's body.

REPORT COVERAGE

This report covers the autoimmune disease treatment market by type, application, region and company, with analysis of market dynamics, latest trends, investment activity, product development and competitive positioning. Type coverage includes Immunosuppressants, Anti-Inflammatory Drugs, Corticosteroids, Nonsteroidal Anti-inflammatory Drugs and Biologics, while application coverage spans Hospitals, Clinics, Drug Stores and Other. Regional coverage includes North America, Europe, Asia Pacific, Middle East & Africa and Rest of the World. The company analysis reviews 15 leading vendors, including Johnson & Johnson and Amgen, and explains how regulatory approvals, reimbursement, clinical innovation and patient access shape strategy in the autoimmune disease treatment market.